Jan Marsal
1 – 46 of 46
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
2024) In Digestive Diseases and Sciences(
- Contribution to journal › Article
-
Mark
Histologic Remission in Inflammatory Bowel Disease and Female Fertility : A Nationwide Study
2024) In Gastroenterology(
- Contribution to journal › Article
-
Mark
Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device
(
- Contribution to journal › Article
- 2023
-
Mark
Long-term outcomes of vedolizumab in inflammatory bowel disease : the Swedish prospective multicentre SVEAH extension study
(
- Contribution to journal › Article
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
(
- Contribution to journal › Article
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Letter: to switch or not to switch, that is the question—author's reply
(
- Contribution to journal › Letter
-
Mark
A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT : a three-arm parallel blinded randomised controlled single-centre trial
(
- Contribution to journal › Article
-
Mark
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes : A nationwide study
(
- Contribution to journal › Article
- 2021
-
Mark
Lung Mast Cells Have a High Constitutive Expression of Carboxypeptidase A3 mRNA That Is Independent from Granule-Stored CPA3
(
- Contribution to journal › Article
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article
- 2020
-
Mark
Short and long-term efficacy of adalimumab in ulcerative colitis : a real-life study
(
- Contribution to journal › Article
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
-
Mark
Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
(
- Contribution to journal › Article
- 2019
-
Mark
Exocrine pancreatic function is preserved in systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
(
- Contribution to journal › Article
- 2017
-
Mark
Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile
(
- Contribution to journal › Article
-
Mark
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
(
- Contribution to journal › Article
-
Mark
Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
(
- Contribution to journal › Article
-
Mark
Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors' reply
(
- Contribution to journal › Letter
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
-
Mark
Long-term outcome of infliximab treatment in chronic active ulcerative colitis : a Swedish multicentre study of 250 patients
(
- Contribution to journal › Article
- 2016
-
Mark
Diet induced arthritis in pigs: Comment on the Article by Scher et al.
(
- Contribution to journal › Letter
-
Mark
Introduktion av biosimilarer kräver noggrann övervakning.
(
- Contribution to journal › Article
-
Mark
Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease
(
- Contribution to journal › Article
-
Mark
CD8αβ+ γδ T cells : A novel T cell subset with a potential role in inflammatory bowel disease
(
- Contribution to journal › Article
- 2015
-
Mark
A major population of mucosal memory CD4(+) T cells, coexpressing IL-18Rα and DR3, display innate lymphocyte functionality.
(
- Contribution to journal › Article
-
Mark
Recurrent fever caused by Candidatus Neoehrlichia mikurensis in a rheumatoid arthritis patient treated with rituximab.
(
- Contribution to journal › Letter
-
Mark
Multi-locus sequence analysis (MLSA) of clinical "CandidatusNeoehrlichia mikurensis" strains from Europe.
(
- Contribution to journal › Article
-
Mark
Physiological role of TNF in mucosal immunology : Regulation of macrophage/dendritic cell function
2015) p.9-26(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Physiological Role of TNF in Mucosal Immunology : Regulation of Macrophage/Dendritic Cell Function
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2013
-
Mark
IRF4 Transcription-Factor-Dependent CD103(+)CD11b(+) Dendritic Cells Drive Mucosal T Helper 17 Cell Differentiation.
(
- Contribution to journal › Article
- 2012
-
Mark
Targeting T cell migration in inflammatory bowel disease.
(
- Contribution to journal › Article
- 2008
-
Mark
Involvement of CCR9 at multiple stages of adult T lymphopoiesis.
(
- Contribution to journal › Article
- 2006
-
Mark
Gut associated lymphoid tissue primed CD4+ T cells display CCR9 dependent and independent homing to the small intestine.
(
- Contribution to journal › Article
- 2005
-
Mark
beta(1) integrins are not required for the maintenance of lymphocytes within intestinal epithelia.
(
- Contribution to journal › Article
- 2004
-
Mark
Chemokines and Integrins in Lymphocyte Development and Localization
2004)(
- Thesis › Doctoral thesis (compilation)
- 2002
-
Mark
CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa.
(
- Contribution to journal › Article
-
Mark
Involvement of CCL25 (TECK) in the generation of the murine small-intestinal CD8alpha alpha+CD3+ intraepithelial lymphocyte compartment.
(
- Contribution to journal › Article
- 1999
-
Mark
Mucosal T lymphocyte numbers are selectively reduced in integrin α(E) (CD103)-deficient mice
(
- Contribution to journal › Article